LGVNR News

Longeveron Announces Engagement of Lucid Capital Markets

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Longeveron to Present at BIO International Convention 2026

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron Announces Private Placement of up to $30 Million